Pharmaceutical Investing VBI Vaccines Announces Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients
BeiGene Initiates Global Phase 2 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Relapsed or Refractory Mature T-and NK-Cell Lymphomas
BeiGene Initiates Global Phase 2 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Previously Treated Hepatocellular Carcinoma
Pharmaceutical Investing Sarepta Therapeutics Announces Fourth Quarter 2017 and Full-Year 2017 Financial Results
Pharmaceutical Investing Corium Announces Proposed Offering of $100 Million of Convertible Senior Notes
Pharmaceutical Investing BeiGene Announces Approval of REVLIMID® for Newly Diagnosed Multiple Myeloma in China
Pharmaceutical Investing BeiGene Initiates Global Phase 3 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Esophageal Squamous Cell Carcinoma
Strongbridge Biopharma Announces Acquisition of the U.S. and Canadian Rights to MACRILEN™ (macimorelin) from Aeterna Zentaris
Heritage Mining Ltd. Announces Closing of the Second and Final Tranche of its Non-Brokered Private Placement of Units and Flow-Through Units
